POS0876 EFFECT OF ANTI-CD19 CAR T CELL THERAPY IN THE BONE MARROW OF PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES

作者：Ioanna Minopoulou, Adalbert Wilhelm, Fredrik N. Albach, Arnd Kleyer, Edgar Wiebe, Albert Fleischmann, Mareike Frick, Frédérik Damm, Dominic Borie, Vincent Casteleyn, Robert Biesen, Thomas E. Dorner, Tobias Alexander, Jan Zernicke, Lukas Hinkelmann, E. Phitak, Norman Michael Drzeniek, Kamran Movassaghi, Marie Luise Hütter‐Krönke, Eva Schrezenmeier, Adrian Schreiber, Uta Schneider, Georg Schett, L. Bullinger, Gerhard Krönke, O. Penack, David Simón · 发表于：Annals of the Rheumatic Diseases · 年份：2025 · DOI：10.1016/j.ard.2025.06.231 · 被引用次数：1 · 研究领域：CAR-T cell therapy research、Viral Infectious Diseases and Gene Expression in Insects

Background: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has emerged as a promising treatment option for patients with systemic autoimmune diseases that are resistant to conventional therapies [1]. Its efficacy is believed to stem from their ability to eliminate B cells in tissues. Recent findings have demonstrated that anti-CD19 CAR T cell therapy effectively eliminates B cells within the lymph nodes of patients with systemic autoimmune diseases [2], however the impact on the bone marrow remains to be determined. Objectives: To investigate the effect of anti-CD19 CAR T cell therapy in the bone marrow of patients with systemic autoimmune diseases. Methods: Three patients with severe, treatment-resistant systemic autoimmune diseases (Table 1) received autologous anti-CD19 CAR T cell therapy following conditioning therapy with fludarabine and cyclophosphamide [3, 4]. Bone marrow biopsies were performed prior to therapy (Patients 2 and 3) and after therapy (Patient 1 and 2 at week 16, and Patient 3 at week 7). Immune phenotyping of B and T cells was conducted via flow cytometry. Results: Treatment with KYV-101 appeared to be safe (Table 1). Stable clinical improvement was achieved following anti-CD19 CAR T cell therapy, even after discontinuation of all other immunosuppressive treatments. Bone marrow biopsies were performed on two patients (Patients 1 and 3) prior to peripheral B cell reconstitution. In these patients, B cells, particularly CD19+ plasmablasts and CD1...